HK Stock Market Move | ASCLETIS-B (01672) achieves positive top-line results in nearly 3% IL-17 inhibitor ASC50 US Phase I study

ASCLETIS-B (01672) rose nearly 3% recently, up 2.01% at the time of the report to 13.2 Hong Kong dollars, with a turnover of 31.8424 million Hong Kong dollars. In terms of news, on December 15, ASCLETIS-B announced that a Phase I clinical trial (NCT07024602) of ASC50 conducted in the United States achieved positive topline results. The trial was a randomized, double-blind, placebo-controlled study conducted in healthy subjects to evaluate the safety, tolerability, pharmacokinetics, and peripheral circulation binding characteristics of interleukin-17A (IL-17A) targeted by ASC50 using single-ascending dose (SAD) design. Forty-six healthy subjects received 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg of ASC50, or a matching placebo. The study aimed to evaluate safety, tolerability, pharmacokinetics, and targeting binding effects. It is reported that ASC50 is an orally administered small molecule IL-17 inhibitor developed independently by Ascletis. IL-17 has been well validated biologically and has mature commercial value in various autoimmune and inflammatory diseases such as psoriasis. ASC50 is a new chemical entity (NCE) with compound patents in the United States and globally, with patent protection until 2043 (excluding potential patent extensions).